Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             32 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin Grosso, Federica
2012
69 6 p. 1557-1565
artikel
2 9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma Teitelbaum, Aaron M.
2012
69 6 p. 1519-1527
artikel
3 An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors Asahina, Hajime
2012
69 6 p. 1477-1486
artikel
4 An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel Uchiyama, Toshitaka
2012
69 6 p. 1617-1624
artikel
5 A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI) Hida, Naoya
2012
69 6 p. 1625-1631
artikel
6 Ascorbic acid and healthy lymphocytes: a way to explain anticancer activity? Rodemeister, Sandra
2012
69 6 p. 1673-1674
artikel
7 A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults Boni, Joseph P.
2012
69 6 p. 1433-1442
artikel
8 Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study Jansen, Robert S.
2012
69 6 p. 1457-1466
artikel
9 FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model Mudd, Sarah R.
2012
69 6 p. 1669-1672
artikel
10 FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study Zaniboni, Alberto
2012
69 6 p. 1641-1645
artikel
11 Lenalidomide in solid tumors Segler, Angela
2012
69 6 p. 1393-1406
artikel
12 Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies Wang, Zhen-Hua
2012
69 6 p. 1647-1655
artikel
13 Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer Emi, Manabu
2012
69 6 p. 1499-1505
artikel
14 Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions Xia, Binfeng
2012
69 6 p. 1567-1582
artikel
15 Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men Acharya, M.
2012
69 6 p. 1583-1590
artikel
16 Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors Calvo, E.
2012
69 6 p. 1467-1475
artikel
17 Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients Reardon, David A.
2012
69 6 p. 1507-1518
artikel
18 Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients Reardon, David A.

69 6 p. 1507-1518
artikel
19 Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas Dong, Mei
2012
69 6 p. 1413-1422
artikel
20 Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer Asakuma, Maiko
2012
69 6 p. 1529-1536
artikel
21 Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies Bose, Prithviraj
2012
69 6 p. 1657-1667
artikel
22 Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity Al Safarjalani, Omar N.
2012
69 6 p. 1449-1455
artikel
23 Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent Rayburn, Elizabeth
2012
69 6 p. 1423-1431
artikel
24 Reply Hadi, S. M.
2012
69 6 p. 1675
artikel
25 RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR Liu, Ziwei
2012
69 6 p. 1633-1640
artikel
26 Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines Mueller, Annett
2012
69 6 p. 1601-1615
artikel
27 TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules Liu, Qian
2012
69 6 p. 1487-1498
artikel
28 The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib Grossi, Francesco
2012
69 6 p. 1407-1412
artikel
29 The Rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells Takeba, Yuko
2012
69 6 p. 1545-1555
artikel
30 The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum Xie, Fa-Jun
2012
69 6 p. 1443-1448
artikel
31 The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens Lamas, M. J.
2012
69 6 p. 1591-1599
artikel
32 Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients Kume, Manabu
2012
69 6 p. 1537-1544
artikel
                             32 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland